


Clinical Trial Design in Crohn's Disease

Contemporary clinical trial designs in CD can be broadly categorized into two types:
Response-based re-randomization and **treat-through**


Response-based re-randomization (also called *randomized withdrawal design*)¹⁻³

Patients are re-randomized at the start of maintenance, based on their response at the end of the active induction period



Treat-through^{1,2}

Patients continue in existing treatment arm regardless of response at the end of the induction period



^aDepending on the specific design of the study and its objectives, all patients receiving PBO induction, or PBO induction responders may also receive active treatment during maintenance.²

^bDepending on the specific design of the study and its objectives, there may be an active comparator arm in addition to or in place of a PBO arm.⁴

CD=Crohn's Disease; PBO=Placebo.

1. Welty M, et al. *Curr Med Res Opin.* 2020;36(4):595-606. 2. Barberio B, et al. *Dig Liver Dis.* 2024;56(1):7-14. 3. Nair B. *Indian Dermatol Online J.* 2019;10(2):193-201.

4. Jairath V, et al. *J Crohns Colitis.* 2024;18(Suppl. 1):i62-i64.

MMAT-06457 © 2026 Lilly USA, LLC. All rights reserved.